1. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020.
2. Abbas AK, Lichtman AH. Cellular and Molecular Immunology. 10th ed. Elsevier; 2021.
3. Janeway CA, et al. Immunobiology. 9th ed. Garland Science; 2020.
4. Cameron MJ, Kelvin DJ. Cytokines, chemokines and their receptors. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000–2013.
5. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med 2005;353:1711–1723.
6. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995;270:283–286.
7. Schleimer RP, Freeland HS, Peters SP, Brown KE, Derse CP. Effects of glucocorticoids on neutrophil functions. J Pharmacol Exp Ther 1989;250:598–605.
8. Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2017;12:CD007720.
9. Briel M, Spoorenberg SMC, Snijders D, et al. Corticosteroids in patients hospitalized with community-acquired pneumonia. Clin Infect Dis 2018;66:346–354.
10. Infectious Diseases Society of America. Community-acquired pneumonia in adults guideline. Available at: https://www.idsociety.org.
11. Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for severe community-acquired pneumonia. Intensive Care Med 2023;49:615–632.
12. Türk Toraks Derneği. Erişkinlerde Toplumda Gelişen Pnömoniler Tanı ve Tedavi Uzlaşı Raporu. 2021.
13. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693–704.
14. WHO REACT Working Group. Association between systemic corticosteroids and mortality in COVID-19. JAMA 2020;324:1330–1341.
15. Bhimraj A, Morgan RL, Shumaker AH, et al. IDSA guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 2024;78:e250–e349.
16. T.C. Sağlık Bakanlığı. COVID-19 (SARS-CoV-2 Enfeksiyonu) Tanı ve Tedavi Rehberi. 2025. https://hsgm.saglik.gov.tr/depo/Yayinlarimiz/Rehberler/covid19_tani_tedavi.pdf?fbclid=PAZXh-
0bgNhZW0CMTEAc3J0YwZhcHBfaWQPNTY3MDY3MzQzMzUyNDI3AAGn9VeOnSO0qzj3gIXjf72yEsFQZLo1qOe0S7kDYHMoDnNFVCtyKgyHnMC_uFU_aem_NusJjFdESIJTRb-
DE3V55sA (Son erişim: 9 Aralık 2025)
17. National Institutes of Health. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. 2023 update.
18. Inoue N, Fushimi K. Adjunctive corticosteroids in non-HIV Pneumocystis pneumonia. Int J Infect Dis 2019;79:109–115.
19. Lemiale V, Resche-Rigon M, Zerbib Y, et al. Adjunctive corticosteroids in severe Pneumocystis jirovecii pneumonia. Lancet Respir Med 2025;13:800–808.
20. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign guidelines 2021. Intensive Care Med 2021;47:1181–1247.
21. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2015;9:CD004405.
22. van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline for acute bacterial meningitis. Clin Microbiol Infect 2016;22(Suppl 3):S37–S62.
23. World Health Organization. Guidelines for Treatment of Tuberculosis. 2019.
24. Nahid P, Dorman SE, Alipanah N, et al. Treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016;63:e147–e195.
25. Baddley JW, Cantini F, Goletti D, et al. ESGICH consensus on anti-TNF-α agents. Clin Microbiol Infect 2018;24(Suppl 2):S10–S20.
26. Winthrop KL, Mariette X, Silva JT, et al. ESGICH consensus on agents targeting interleukins and complement. Clin Microbiol Infect 2018;24(Suppl 2):S21–S40.
27. Kyriazopoulou E, Poulakou G, Milionis H, et al. Early anakinra treatment in COVID-19. Nat Med 2021;27:1752–1760.
28. Gulick RM, Pau AK, Daar E, et al. NIH COVID-19 Treatment Guidelines Panel perspectives. Ann Intern Med 2024;177:1547–1557.
29. Bhimraj A, Morgan RL, Shumaker AH, et al. IDSA COVID-19 treatment guidelines. Clin Infect Dis 2024;78:e250–e349.
30. Reinwald M, Silva JT, Mueller NJ, et al. ESGICH consensus on tyrosine kinase and mTOR inhibitors. Clin Microbiol Infect 2018;24(Suppl 2):S53–S70.
31. Wollenhaupt J, Lee EB, Curtis JR, et al. Long-term safety of tofacitinib. Arthritis Res Ther 2019;21:89.
32. Redelman-Sidi G, Michielin O, Cervera C, et al. ESGICH consensus on immune checkpoint inhibitors. Clin Microbiol Infect 2018;24(Suppl 2):S95–S107.
33. Dinarello CA. Cytokines and cytokine therapies. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 10th ed. Elsevier; 2020.
34. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Antimicrobial use in neutropenic cancer patients. Clin Infect Dis 2011;52:e56–e93.
35. Kricker JA, Page CP, Gardarsson FR, Baldursson O, Gudjonsson T, Parnham MJ. Nonantimicrobial actions of macrolides: overview and perspectives for future development. Pharmacol Rev
2021;73:233–262.
36. Tauber SC, Nau R. Immunomodulatory properties of antibiotics. Curr Mol Pharmacol 2008;1:68–79.
37. Sauer A, Peukert K, Putensen C, Bode C. Antibiotics as immunomodulators in ARDS. Eur Respir Rev 2021;30:210093.
38. Ballow M, Shehata N. Overview of intravenous immune globulin (IVIG) therapy. In: Orange JS, section editor; Tirnauer JS, Feldweg AM, deputy editors. UpToDate. Erişim tarihi: 10 Aralık
2025. URL: https://www.uptodate.com
39. T.C. Sağlık Bakanlığı. Kuduz Profilaksi Rehberi. 2019.
40. Demirtürk N, Köse A, Ural O, et al. Chronic hepatitis B management consensus report. Klimik Derg 2023;36(Suppl 1):1–22.
41. Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Diagnosis and treatment of botulism. MMWR Recomm Rep 2021;70:1–30.
42. Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recomm Rep. 2021.
43. FDA. FDA announces Evusheld is not currently authorized for emergency use in the U.S. Update 01/26/2023.
44. FDA. Fact Sheet for Healthcare Providers: Emergency Use Authorization of PEMGARDA (pemivibart). Original EUA Authorized Date: 03/2024.
45. CDC ACIP. Evidence to Recommendations for Use of Nirsevimab for Infants and Children in Their Second RSV Season.
46. Johnson S, Lavergne V, Skinner AM, et al. IDSA/SHEA guideline on Clostridioides difficile infection. Clin Infect Dis 2021;73:e1029–e1044.
47. Albrecht MT, Li H, Williamson ED, et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen protect against Bacillus anthracis infection. Infect Immun
2007;75:5425–5433.